口服艾斯拉韦每月一次用于HIV暴露前预防的安全性:IMPOWER-24随机3期研究
IMPOWER-24是一项双盲3期研究,在494名有较高HIV-1暴露风险的顺性别男性和跨性别女性中,按2:1随机接受艾斯拉韦60mg口服每月一次或每日一次FTC/TDF或FTC/TAF。因淋巴细胞减少,盲法艾斯拉韦约9个月后停止,开放标签对照延长20个月。艾斯拉韦组总体耐受性良好,但第3个月总淋巴细胞较基线下降7.4%,停药后呈恢复趋势;双盲阶段两组均无HIV感染。
要点
- 艾斯拉韦每月一次总体耐受性良好,多数不良事件为轻中度。
- 艾斯拉韦组第3个月总淋巴细胞较基线下降7.4%,停药后呈恢复趋势。
- 因淋巴细胞减少提前终止盲法艾斯拉韦,原主要疗效目标未评估。
核心结论
- 艾斯拉韦60mg口服每月一次总体耐受性良好,但观察到总淋巴细胞下降,停药后呈恢复趋势。
- 因研究提前停止,原主要疗效目标未评估;双盲阶段两组均无HIV感染。
研究设计与样本
- IMPOWER-24(NCT04652700)为双盲3期研究,共纳入494名有较高HIV-1暴露风险的顺性别男性和跨性别女性。
- 参与者按2:1随机接受艾斯拉韦60mg口服每月一次(328人)或每日一次FTC 200mg联合TDF 245mg或TAF 25mg(166人)。
- 盲法艾斯拉韦约9个月后因淋巴细胞减少停止,随后提供开放标签对照20个月。
主要发现
- 艾斯拉韦组211人(64.3%)、对照组128人(77.1%)发生至少1例不良事件,大多为轻中度。
- 艾斯拉韦组有1例不良事件(胃食管反流)导致产品停用;严重不良事件发生率<2%,均与研究产品无关。
- 艾斯拉韦组第3个月总淋巴细胞较基线变化为-7.4%,停药后呈恢复趋势,平均总淋巴细胞仍在正常范围内。
- 双盲阶段两组均无HIV感染。
关键数值与推荐
- 艾斯拉韦用法为60mg口服每月一次;对照为FTC 200mg联合TDF 245mg或TAF 25mg每日一次。
- 盲法艾斯拉韦因淋巴细胞减少在约9个月后停止;艾斯拉韦组第3个月总淋巴细胞变化为-7.4%。
- 严重不良事件发生率<2%,且均与研究产品无关。
临床怎么用
- 艾斯拉韦每月一次方案在研究中总体耐受性良好,但需关注总淋巴细胞变化。
- 因淋巴细胞减少导致研究提前终止,原主要疗效目标未评估,临床决策需结合后续数据。
局限性
- 研究因淋巴细胞减少提前停止,原主要疗效目标未评估。
- 盲法给药平均持续时间较短(艾斯拉韦4.7个月,对照4.3个月)。
- 开放标签对照延长20个月,但盲法阶段安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Islatravir once monthly (qm), a nucleoside reverse transcriptase translocation inhibitor with a long half-life, was evaluated for safety and tolerability in cisgender men and transgender women who have sex with men and are at increased likelihood of HIV-1 (HIV) exposure. METHODS: IMPOWER-24 (NCT04652700) was a double-blind, Phase 3 study. Participants were randomized 2:1 to islatravir 60 mg oral qm or emtricitabine (FTC; 200 mg) coformulated with either tenofovir disoproxil (245 mg) or tenofovir alafenamide (TAF; 25 mg) once daily (qd). After ∼9 months, blinded islatravir was discontinued due to lymphocyte reductions; participants were offered open-label comparator for 20 months. RESULTS: In total, 494 participants were enrolled (328 islatravir; 166 comparator): 91.5% were cisgender men, 41.7% were White, and median age was 27 years. Mean blinded dosing duration was 4.7 months (islatravir) versus 4.3 months (comparator). Overall, 211 participants (64.3%) in the islatravir group and 128 (77.1%) in the comparator group had ≥1 adverse event (AE). Most AEs were mild or moderate, with 1 AE leading to product discontinuation (islatravir; gastroesophageal reflux). Serious AEs occurred in <2%; none were related to study product. Change in total lymphocytes in the islatravir group at Month 3 was -7.4%; a trend toward recovery was observed after islatravir was stopped. Mean total lymphocytes remained within normal range. No HIV infections occurred in either group during the double-blind phase. CONCLUSIONS: Islatravir qm was generally well tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.
引用
- Landovitz RJ, Pinedo Y, Hinestrosa F, et al. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study. Clin Infect Dis. 2026. PMID: 41830344. doi:10.1093/cid/ciag171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。